Abstract
Since several clinical data have suggested that the incidence of neurological deficit after aortic surgery has not changed appreciably over the last 50 years, anesthesiologists as well as vascular surgeons have attempted to resolve this clinically important issue by employing various strategies to prevent ischemic spinal cord injury. With respect to inhalational anesthetics, it is thought that isoflurane as well as sevoflurane preconditioning might provide neuroprotective effects against spinal ischemia via activation of TWIK-related K channels-1 or the potassium ATP channel. Glutamate receptor antagonists, including ketamine, could also potentially provide some neuroprotection against spinal ischemia. However, it seems likely that decreased glutamate release could produce more neuroprotective effects against spinal ischemia than a blockade of the glutamate receptor. Although barbiturate alone failed to protect the spinal cord, a controversial issue has been the possible neuroprotective effects associated with local anesthetics including tetracaine, lidocaine and bupivacaine. Clinical cases and experimental studies have indicated that neuraxial opioids might be capable of exacerbating neurological deficits even after a non-injurious interval of spinal ischemia. Inhaled nitric oxide (iNO) therapy (40-80ppm), a common treatment for pulmonary hypertension, has been reported to prevent ischemic brain injury in animal studies by selective dilation of collateral arterioles. The vasodilating effects of iNO on the central nervous system might enhance the “collateral network” in the spinal cord during aortic cross-clamp, potentially protecting the spinal cord. In conclusion, some anesthetics, especially inhalational anesthetics, may provide neuroprotective effects against spinal cord ischemia, but administration of neuraxial opioid after spinal cord ischemia might exacerbate neurological dysfunction.
Keywords: Spinal cord ischemia, aortic cross-clamp, immediate paraplegia, delayed paraplegia, apoptosis, inhalational anesthetics, Opioid, Nitric Oxide.
Current Pharmaceutical Design
Title:Protective Effects of Anesthetics on the Spinal Cord
Volume: 20 Issue: 36
Author(s): Manabu Kakinohana
Affiliation:
Keywords: Spinal cord ischemia, aortic cross-clamp, immediate paraplegia, delayed paraplegia, apoptosis, inhalational anesthetics, Opioid, Nitric Oxide.
Abstract: Since several clinical data have suggested that the incidence of neurological deficit after aortic surgery has not changed appreciably over the last 50 years, anesthesiologists as well as vascular surgeons have attempted to resolve this clinically important issue by employing various strategies to prevent ischemic spinal cord injury. With respect to inhalational anesthetics, it is thought that isoflurane as well as sevoflurane preconditioning might provide neuroprotective effects against spinal ischemia via activation of TWIK-related K channels-1 or the potassium ATP channel. Glutamate receptor antagonists, including ketamine, could also potentially provide some neuroprotection against spinal ischemia. However, it seems likely that decreased glutamate release could produce more neuroprotective effects against spinal ischemia than a blockade of the glutamate receptor. Although barbiturate alone failed to protect the spinal cord, a controversial issue has been the possible neuroprotective effects associated with local anesthetics including tetracaine, lidocaine and bupivacaine. Clinical cases and experimental studies have indicated that neuraxial opioids might be capable of exacerbating neurological deficits even after a non-injurious interval of spinal ischemia. Inhaled nitric oxide (iNO) therapy (40-80ppm), a common treatment for pulmonary hypertension, has been reported to prevent ischemic brain injury in animal studies by selective dilation of collateral arterioles. The vasodilating effects of iNO on the central nervous system might enhance the “collateral network” in the spinal cord during aortic cross-clamp, potentially protecting the spinal cord. In conclusion, some anesthetics, especially inhalational anesthetics, may provide neuroprotective effects against spinal cord ischemia, but administration of neuraxial opioid after spinal cord ischemia might exacerbate neurological dysfunction.
Export Options
About this article
Cite this article as:
Kakinohana Manabu, Protective Effects of Anesthetics on the Spinal Cord , Current Pharmaceutical Design 2014; 20 (36) . https://dx.doi.org/10.2174/1381612820666140204114124
DOI https://dx.doi.org/10.2174/1381612820666140204114124 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews Thrombocytopenia in HIV Disease: Clinical Relevance, Physiopathology and Management
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Microcirculatory Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Update in the Management of Diabetic Nephropathy
Current Diabetes Reviews Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Nitrergic Modulation of Gastrointestinal Function During Early Endotoxemia
Current Pharmaceutical Design Characterization and Antihypertensive Effect of the Complex of (-)-β- pinene in β-cyclodextrin
Current Pharmaceutical Biotechnology Rediscovery of Caffeine: An Excellent Drug for Improving Patient Outcomes while Fighting WARS
Current Medicinal Chemistry The Use of Novel Oral Anticoagulants in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Antihypertensive Effect of Sesamin
Vascular Disease Prevention (Discontinued)